Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

Author:

Scagliotti Giorgio V.,Park Keunchil,Patil Shekar,Rolski Janusz,Goksel Tuncay,Martins Renato,Gans Steven J.M.,Visseren-Grul Carla,Peterson Patrick

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Management of metastatic non-small cell lung cancer in 2006: innovations and unique clinical scenarios;Martins,2006

2. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. National Comprehensive Cancer Network. ; 2009 [accessed 31.03.09].

3. ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;D’Addario;Ann Oncol,2008

4. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial;Manegold;Ann Oncol,2000

5. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group;Shepherd;Cancer,2001

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3